Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs

Selexis, OSE Team Up to Advance Two Cancer Immunotherapy Programs

Selexis and OSE Immunotherapeutics have signed two commercial license agreements (CLAs) to advance the clinical development of two new cancer immunotherapy programs, OSE-172 and OSE-703.

The agreement supports the development of OSE’s new generation immune myeloid checkpoint inhibitor (OSE-172) and cytotoxic monoclonal antibody targeting the IL-7 receptor (OSE-703).

OSE-172 is a monoclonal antibody that blocks the generation of pro-tumor suppressor cells and restores their anti-tumoral function. OSE-172 blocks SIRP-alpha (Signal Regulatory Protein Alpha), a receptor strongly expressed by myeloid and macrophage suppressor cells in the tumor microenvironment.

The product helps modifying tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) associated with a poor prognosis by blocking and transforming them into cells with a good prognosis.

OSE-172 also may be combined with other immunotherapies, in particular with checkpoint inhibitors acting on T-lymphocytes, such as products triggering a stimulation of the immune system. This new product is anticipated to enter Phase 1/2 clinical trials in 2018.

OSE-703 is a humanized monoclonal antibody targeting the extracellular domain of the IL-7 receptor (IL-7R), killing cells positive for the receptor.

Under collaboration with Memorial Sloan Kettering Cancer Center, the immuno-oncology therapeutic candidate is in preclinical studies for solid tumors with non-small cell lung cancer (NSCLC) as the primary cancer model.

In a study published in the Journal of Clinical Oncology in February 2013, titled “Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence,” researchers showed that IL-7R was overexpressed in NSCLC and associated with poor prognosis.

“This is our third signed CLA with OSE this year, and we believe the rapid expansion of our relationship is a direct result of the utility and flexibility of our cell-line expression technology across protein therapeutics and development stages,” Marco Bocci, PhD, vice president of licensing and business development at Selexis, said in a press release. “Selexis’ technology can scale with OSE’s developmental needs, and provide the company with a fast, stable and reliable method of protein expression. This is critical for the development of recombinant, protein-based medicines like OSE-172 and OSE-703.”

The agreements provide OSE with access to Selexis’ high-performance research cell banks (RCBs) developed using their SUREtechnology Platform, which facilitates the stable and cost-effective production of recombinant proteins and provides integration of the biologics development continuum from discovery to commercialization.